Zusammenfassung
Glaukom ist in Deutschland die zweithäufigste Ursache irreversibler Erblindungen.
Es stehen verschiedene therapeutische Ansätze zur Verfügung. Neben der Verbesserung
der vaskulären Perfusion und der Reduktion des oxidativen Stresses steht als zentrale
Therapieoption nach wie vor die Senkung des Augeninnendrucks im Vordergrund. Dafür
kommen verschiedene Wirkstoffklassen mit unterschiedlichem Wirkmechanismus und Nebenwirkungsprofil
zur Anwendung.
Abstract
Glaucoma is the leading cause of irreversible blindness in Germany and in the world.
Due to the multifactorial genesis of the disease, there are multiple therapeutic approaches
for preventing its progression. The goal of the commonly used topical glaucoma medication
is to reduce the intraocular pressure and therefore prevent further damage to the
optic nerve. There are different medications of various pharmacological classes that
are intended to reduce intraocular pressure, namely, β-adrenergic antagonists, adrenergic
agonists, parasympathomimetic agents, prostaglandin analogues, carbonic anhydrase
inhibitors, hyperosmotic agents, and the 2017 U. S. FDA approved Rho kinase inhibitor,
Netarsudil.
After determining a patient centered target pressure, which depends upon various factors,
an individual treatment regimen should be chosen with one or more agents. Although
reducing the intraocular pressure remains the main therapeutic focus, there is increasing
evidence indicating that oxidative stress also plays a key role in the pathogenesis
of the primary open angle glaucoma. Therefore, direct and indirect neuroprotective
agents like Magnesium, Coenzym Q10, Ginkgo biloba and others are getting more and
more attention. While there is still a need for further clinical trials, these substances
are getting more popular as an adjunct in glaucoma therapy.
Schlüsselwörter
Glaukomtherapie - medikamentöse Drucksenkung - Rho-Kinase-Hemmer - Neuroprotektion
Key words
glaucoma - medical management - intraocular pressure - Rho kinase inhibitor - neuroprotection
